Aselizumab
From Wikipedia, the free encyclopedia
Aselizumab is an immunosuppressive drug which has been investigated for the use in severely injured patients. It binds to CD62L.[1]
[edit] References
- ^ Seekamp, A; Van Griensven, M; Dhondt, E; Diefenbeck, M; Demeyer, I; Vundelinckx, G; Haas, N; Schaechinger, U et al (2004). "The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial". Critical care medicine 32 (10): 2021–8. doi:10.1097/01.CCM.0000142396.59236.F3. PMID 15483410.
|
|
|
Intracellular
(initiation) |
|
|
Intracellular
(reception) |
|
|
| Extracellular |
|
|
|
|
|
Serum target
(noncellular)
|
|
|
|
Cellular target
|
|
|
|
Unsorted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immune system ("-l(i[m])-") |
|
Human ("-limu-")
|
|
|
|
Mouse ("-limo-")
|
|
|
|
|
|
|
|
|
|
|
|
Chimeric + humanized
("-lixizu-")
|
|
|
|
| Interleukin ("-k(i[n])-") |
|
Human ("-kinu-")
|
|
|
|
Humanized ("-kizu-", "-kinzu-")
|
|
|
|
| Inflammatory lesions ("-les-") |
|
|
|
|
|
(what is this?) (verify)
